.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The World Health Organization (WHO) recently highlighted several experimental Bundibugyo Ebola treatments for clinical trials. Currently, an active outbreak of this rare Ebola strain is affecting the Democratic Republic of the Congo and Uganda. Because there are no approved therapies or vaccines for this specific strain, health authorities must evaluate these candidates urgently.
The expert panel recommended evaluating three experimental therapeutics. Specifically, these include Mapp Biopharmaceutical's MBP134, Regeneron's monoclonal antibody maftivimab, and Gilead's antiviral remdesivir. Additionally, advisors suggested testing a combination of a monoclonal antibody and remdesivir. Consequently, clinical trials will help establish efficacy data. Meanwhile, Regeneron has already supplied maftivimab to the Democratic Republic of the Congo for prospective research.
For post-exposure prophylaxis, Gilead’s oral antiviral obeldesivir is a leading candidate. However, its success heavily relies on robust contact tracing. Furthermore, the International AIDS Vaccine Initiative is developing a single-dose vaccine candidate called rVSV Bundibugyo. Although this vaccine is promising, it will not be ready for trials for seven to nine months. Alternatively, the ChAdOx1 Bundibugyo vaccine, developed by Oxford and the Serum Institute, may be ready in three months. Nevertheless, researchers still need more animal data for this candidate. Finally, the WHO advised against using Merck's Ervebo vaccine outside research settings due to inconclusive protection data.
Q1: Are there any approved vaccines for the Bundibugyo strain of Ebola?
Currently, there are no approved vaccines or therapies specifically licensed for the Bundibugyo virus disease.
Q2: What treatments are being prioritized for clinical trials?
The WHO recommends clinical trials for MBP134, maftivimab, and remdesivir, including potential combination therapies.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The WHO identifies experimental treatments and vaccines for clinical trials during the active Bundibugyo Ebola outbreak in the DRC and Uganda....
3 months ago
A 2026 meta-analysis evaluates PDE5 inhibitors in advanced ILD with severe gas exchange impairment. While overall mortality was not significantly reduced, a targeted subgroup with pulmonary hypertension showed a 49% risk reduction, underscoring the necessity of precise hemodynamic phenotyping.
Today
At the 79th Regional Committee session, the World Health Organization commended India's public health advancements. Key achievements include the operationalization of 160,000 Ayushman Arogya Mandirs, higher institutional delivery rates, strong ASHA networks, and persistent efforts to eliminate tuberculosis nationwide.
Today
The Supreme Court questioned FSSAI's phased warning approach, urging single-phase implementation for foods exceeding limits in any nutrient of concern. Backed by ICMR-NIN recommendations, the proposed red hexagonal warnings target added sugar, salt, and fat to combat India's escalating chronic disease epidemic.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
A comparative analysis shows that older age, elevated blood glucose, and abdominal adiposity are primary drivers of hypertension. Comprehensive evaluation of cardiometabolic risk profiles enables clinicians to detect overlapping metabolic dysfunctions early and optimize targeted prevention strategies.
Today
